Panacea Biotec Pharma Receives ₹4.06 Cr GST Show Cause Notice

Panacea Biotec Pharma Ltd., a wholly owned subsidiary of Panacea Biotec Ltd., has received a Show Cause Notice (SCN) dated July 23, 2026, from the Assistant Commissioner, Goods and Services Tax (GST), Delhi. The notice alleges a total tax liability of ₹4.06 Crore, including tax, interest, and penalty, for the Financial Year 2022-23. The alleged discrepancy pertains to an excess claim of Input Tax Credit (ITC) in the annual return filed for that period. The company is currently collating details to prepare a response and does not foresee any adverse financial or operational impact from this notice at this stage.